PubMed Health⌕ Search

Biomedical subjects

S Morello

Publications and source records attributed to S Morello.

7 recordsLinked to original sources
PubMed2001

MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.

Oral squamous cell carcinoma (SCC) is a neoplasm characterized by a high degree of local invasion and an elevated rate of metastasis to cervical lymph nodes. It has been shown that the Hepatocyte Growth Factor/Scatter Factor Receptor Met is constitutively activated in many human tumors of epithelial origin and that it plays a critical role to confer invasive properties to neoplastic cells. Most frequently, Met activation is due to receptor overexpression, but also point mutations in the tyrosine kinase domain can lead to deregulated activation. Here we show that in all the primary tumors examined this receptor is overexpressed. Direct sequencing of Met mRNAs failed to find any activating mutation in its intracellular domain. Moreover, in cell lines derived from squamous cell carcinomas, HGF-induced activation of Met resulted in the acquisition of invasive properties. All together these data suggest that the MET oncogene is involved in progression of squamous cell carcinoma toward an invasive-metastatic behavior.

Adult↗
PubMed1990

Effect of topically administered epidermal growth factor on corneal wound strength.

A 9-mm perforating corneal wound was created in one eye of New Zealand albino rabbits, sutured, and treated with mouse-derived epidermal growth factor (1 mg/L), human-derived epidermal growth factor (1.0 mg/L to 100 mg/L), or buffered saline, instilled once, twice, or four times daily. Both mouse-derived epidermal growth factor and human-derived epidermal growth factor significantly increased the tensile strength of full-thickness corneal wounds after 9 days of topical therapy. For human-derived epidermal growth factor, a concentration of 10 mg/L administered twice daily produced the maximal effect. An increase in either the concentration of epidermal growth factor or its frequency of administration failed to induce a further increase in wound strength. Indeed, at a concentration of 100 mg/L, human-derived epidermal growth factor appeared to lose its ability to accelerate healing of full-thickness corneal wounds.

Administration, Topical↗
PubMedDate not supplied

Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.

In 14 patients with cirrhosis and chronic portosystemic encephalopathy, the effectiveness of treatment with a new non-assorbable antibiotic (rifaximine) was compared to neomycin. The parameters evaluated were: bradylalia, flapping tremor, performance, visual evoked potentials and the trial making test. Both treatments were combined with lactulose. The analysis of results showed a rate of positive results in the patients treated with rifaximine greater than that with neomycin. Differences, however, were not significant.

Chronic Disease↗